/Investor DB

Domain Associates — Full Portfolio

59 tracked investments · listed companies and verified rows first

Aldeyra Therapeuticsaldeyra.cominNASDAQ: ALDXJan 2015

Aldeyra Therapeutics is a biopharmaceutical company developing therapies for eye diseases and other conditions.

BiotechHealthtechMedical DevicesLexington, US

Todd C. Brady(Executive Officer, Director)inStephen Tulipano(Executive Officer)inScott L. Young(Executive Officer)inDr. Brady(President and Chief Executive Officer)

BoardJesse I. Treu(Director)inBen Bronstein(Director)

Board seatJesse Treu· per SEC Form D

Bionano Genomicsbionano.comNASDAQ: BNGOSep 2014SEC filingmedium confidence

Bionano develops optical genome mapping (OGM) systems and analysis software that detect structural variants and chromosomal aberrations across the genome.

BiotechHealthtechMedical DevicesSan Diego, US

Han Cao(Executive Officer)Gulsen Kama(Executive Officer)Mark Oldakowski(Executive Officer)inJonathan Dixon(Executive Officer)inR. Erik Holmlin(Executive Officer, Director)Alka Chaubey(Executive Officer)in

Board seatBrian Halak· per SEC Form D · $68.4M raise · filed Jan 2015

Co-investorsHudson Bay

Evofem BiosciencesinOTC: EVFMApr 2020SEC filingmedium confidence

Evofem Biosciences is a biopharmaceutical company that commercializes products for women's sexual and reproductive health, including PHEXX, a non-hormonal prescription vaginal contraceptive gel applied before intercourse, and SOLOSEC, an oral antimicrobial agent for treating bacterial vaginosis and trichomoniasis.

BiotechSan Diego, US

Ivy Zhang(Executive Officer)inSaundra Pelletier(Executive Officer, Director)inKelly Culwell(Executive Officer)inJustin J. File(Executive Officer)inAlexander A. Fitzpatrick(Executive Officer)Russell Barrans(Executive Officer)

Board seatKim Kamdar· per SEC Form D · $25M raise · filed May 2020

Co-investorsAdjuvant CapitalInvescoWoodford Investment Management

Align Technologyaligntech.comin𝕏NASDAQ: ALGN

Align Technology is a medical device company that makes clear aligners (the Invisalign System) and intraoral scanners for orthodontic and restorative dental treatment.

HardwareHealthtechMedical DevicesMorrisville, US

Kelsey Wirth(Founder)Zia Chishti(Founder)

Co-investorsKleiner PerkinsQuestMark Partners

Atara Biotherapeuticsatarabio.comin𝕏NASDAQ: ATRA

Atara Biotherapeutics develops allogeneic T-cell immunotherapies using its proprietary EBV T-cell platform to harness the immune system for treating disease.

BiotechHealthtechMedical DevicesThousand Oaks, US

AnhCo Nguyen(President and Chief Executive Officer)Isaac Ciechanover(Founder)

Co-investorsDag VenturesEcoR1 CapitalHEALTHCARE ROYALTY PARTNERSKleiner PerkinsFidelity Investments

aTYR PHARMAatyrpharma.comin𝕏NASDAQ: ATYRSeries C · Oct 2010 · $23M

aTyr is a clinical-stage biotechnology company developing therapies derived from tRNA synthetase biology to treat fibrosis and inflammation, with its lead candidate efzofitimod in clinical trials for interstitial lung disease.

BiotechHealthtechMedical DevicesSan Diego, US

Paul Schimmel(Founder)John D. Mendlein(Executive Officer, Director)David Weiner(Executive Officer)inFrederic Chereau(Executive Officer)

BoardAmir Nashat(Non-Management Director)inAkkaraju Srinivas(Non-Management Director)

Co-investorsCardinal PartnersEcoR1 CapitalSofinnova VenturesViking GlobalDomain PartnersPolaris Partners+2 more

Fractylfractyl.comin𝕏NASDAQ: GUTS

Fractyl develops therapies for obesity and type 2 diabetes, focusing on non-drug-based approaches rooted in understanding metabolic disease mechanisms.

BiotechHealthtechMedical DevicesLexington, US

Jay Caplan(Founder)inHarith Rajagopalan(Co-Founder and CEO)inLISA DAVIDSON(Executive Officer)inDiane Marcou(Executive Officer)in

BoardAllan Will(Director)inNimesh Shah(Director)in

Co-investorsBessemer Venture PartnersCatalio Capital Management, LPEmergent Medical Partners, LLPGeneral CatalystMithril Capital ManagementPolaris Partners+1 more

Gerongeron.cominNASDAQ: GERN

Geron is a biopharmaceutical company focused on developing therapies for blood cancer.

BiotechHealthtechLongevityMedical Devices

Michael D. West(Founder)Harout Semerjian(President and Chief Executive Officer)inMichelle J. Robertson(Executive Vice President, Chief Financial Officer, Treasurer and Interim Secretary)inJoseph Eid(Executive Vice President, Research and Development, Chief Medical Officer)inAhmed ElNawawi(Executive Vice President, Chief Commercial Officer)in

Co-investorsBioBritNew Enterprise Associates (NEA)Venrock

Sera Prognosticsseraprognostics.comin𝕏NASDAQ: SERA

Sera Prognostics develops women's health diagnostics focused on pregnancy, including the PreTRM blood test that predicts an individual's risk of spontaneous preterm birth in singleton pregnancies and the LikeMine platform that compares pregnancy outcomes using U.S. pregnancy data.

BiotechDigital HealthFemTechHealthtechSalt Lake City, US

Douglas Fisher(Executive Officer)Jay Moyes(Executive Officer)inGregory C. Critchfield(Executive Officer, Director)inAndrew A. Sauter(Executive Officer)inZhenya Lindgardt(President and Chief Executive Officer)in

BoardMansoor Mirza(Director)

Co-investorsaMoonExcelestar VenturesIntermountain HealthOUP (Osage University Partners)UpStart VenturesVivo Capital+1 more

Syndax Pharmaceuticalssyndax.cominNASDAQ: SNDXSeries A · Apr 2007 · $40M

Syndax Pharmaceuticals is a commercial-stage biopharmaceutical company that develops and commercializes small-molecule and antibody cancer therapies, including two FDA-approved medicines: revumenib (a menin inhibitor for acute leukemias) and axatilimab (a CSF-1R blocking antibody for graft-versus-host disease and fibrotic diseases), along with clinical-stage programs exploring expanded uses and combinations in oncology.

BiotechWaltham, US

John Pallies(Executive Officer)inArlene Morris(Executive Officer, Director)inMichael A. Metzger(Chief Executive Officer)inKeith A. Goldan(Chief Financial Officer)in

BoardDennis Podlesak(Director)inIvor Royston(Director)

Co-investorsAisling CapitalATEM Capital FundAvoro Capital AdvisorsBioBritDelos CapitalEcoR1 Capital+6 more

Tandem Diabetes Care, Inc.tandemdiabetes.comNASDAQ: TNDMSeries B · Jul 2008 · $13M

Tandem Diabetes manufactures infusion sets—tubing systems with subcutaneous delivery sites—designed for use with insulin pumps to manage diabetes.

Digital HealthHardwareHealthtechMedical Devices

Kim BlickenstaffinJohn Sheridan(President, Chief Executive Officer)inRick Carpenter(Executive Vice President and Chief Technology Officer)inElizabeth Gasser(Executive Vice President and Chief Strategy and Product Officer)inShannon Hansen(Executive Vice President, Chief Legal, Privacy & Compliance Officer and Secretary)inJean-Claude Kyrillos(Executive Vice President, Chief Operating Officer)

Co-investorsHLM Investment Partners

Veracyteveracyte.comin𝕏NASDAQ: VCYTSeries B · Jun 2010 · $28M

Veracyte develops genomic diagnostic tests for cancer, offering laboratory developed tests for thyroid, prostate, bladder, and breast cancers performed in its CLIA-certified, high-complexity labs.

BiotechHealthtechMedical DevicesSouth San Francisco, US

Bonnie H. Anderson(Executive Officer, Director)inJulie Brooks(Executive Officer)inShelly D. Guyer(Executive Officer)inMarc Stapley(Chief Executive Officer)in

BoardSamuel D. Colella(Director)Fred E. Cohen(Director)

Co-investorsCatalyst Health VenturesKleiner PerkinsJohnson & Johnson Innovation – JJDC

Aspen Neuroscienceaspenneuroscience.comin𝕏Apr 2020 · $70M✓ verified

Aspen Neuroscience develops iPSC-derived autologous cell therapies for neurological diseases, with a lead product (ANPD001) in Phase 1/2a clinical trials for Parkinson's disease.

BiotechDeep TechDigital HealthMedical DevicesSan Diego, US

Andrés Bratt-Leal(Co-Founder and Senior Vice President, Research & Development)inANDRÉS BRATT-LEAL, Ph.D.(Co-Founder; Senior Vice President, Research & Development)Damien McDevitt(President and Chief Executive Officer)inDAMIEN MCDEVITT, Ph.D.(President and Chief Executive Officer)

Co-investorsARCH Venture PartnersLifeforce CapitalOrbiMedEDB InvestmentsSection 32Frazier Life Sciences+10 more

Truviantruvianhealth.comin𝕏✓ verified

Truvian builds an on-site blood diagnostics platform that combines clinical chemistry, immunoassay, and hematology testing in a single compact instrument.

BiotechDigital HealthMedical DevicesSan Diego, US

Dena Marrinucci(Co-Founder & Chief Operating Officer)inMichael J. Mina(Chief Medical and Strategy Officer)in

Co-investorsDns CapitalGreatPoint VenturesWittington VenturesEmbark VenturesMedical Excellence CapitalXB Ventures+1 more

Afferent PharmaceuticalsinSeries A · Jul 2015 · $23M

BiotechSan Mateo, US

Anthony Ford(Executive Officer)inMichael Kitt(Executive Officer)inKathleen Sereda Glaub(Executive Officer, Director)in

BoardKevin Starr(Director)inArthur Pappas(Director)Liam Ratcliffe(Director)

Board seatJesse Treu· per SEC Form D

Co-investorsPappas CapitalFidelity InvestmentsJennison AssociatesThird Rock Ventures

Orexigen Therapeuticscurraxpharma.cominSep 2015SEC filingmedium confidence

Currax Pharmaceuticals develops and markets a portfolio of therapies for chronic progressive diseases.

BiotechHealthtechLa Jolla, US

Preston Klassen(Executive Officer)inJoseph Hagan(Executive Officer)Michael Narachi(Executive Officer, Director)Thomas Cannell(Executive Officer)

BoardBrian H. Dovey(Director)in

Board seatBrian DoveyEckard Weber· per SEC Form D · $90M raise · filed Sep 2015

Co-investorsCross Creek AdvisorsMontreux Equity PartnersNew Enterprise Associates (NEA)Sofinnova VenturesDomain Partners

SebaciainMay 2015

HealthtechDuluth, US

Anthony V. Lando(Executive Officer, Director)inTodd Meyer(Executive Officer)inDilip Paithanker(Executive Officer)Robert Leslie(Executive Officer)Dilip Paithankar(Executive Officer)in

BoardRebecca B. Robertson(Director)

Board seatJesse Treu· per SEC Form D

Co-investorsAccuitive Medical VenturesVersant Ventures

SonoTherasonothera.comin𝕏Jun 2026SEC filingmedium confidence

SonoThera is developing a nonviral, non-invasive gene delivery technology that uses ultrasound and microbubbles (ultrasound-mediated delivery) to deliver genetic payloads to targeted sites in a redosable way.

BiotechDeep TechDigital HealthHealthtechSouth San Francisco, US

Kenneth Greenberg(Co-Founder, President & CEO)in

Board seatBrian Halak· per SEC Form D · $125.5M raise · filed Jun 2026

Co-investorsVida VenturesLeaps by BayerARCH Venture PartnersFoothill VenturesIllumina VenturesMedical Excellence Capital+8 more

Achillion Pharmaceuticals, Inc.achillion.com𝕏Aug 2010 · $50M

Achillion conducts research and development focused on addressing rare disease challenges through investigation of new therapeutic targets, modalities, and technologies.

BiotechHealthtech

Co-investorsConnecticut InnovationsPappas CapitalSV Health Investors

Adynxx, Inc.adynxx.comDec 2016

BiotechSan Francisco, US

Donald Manning(Executive Officer)Scott Harris(Executive Officer)Julien Mamet(Executive Officer, Director)Rick Orr(Executive Officer, Director)

BoardDennis Podlesak(Director)inEckard Weber(Director)

Co-investorsRed Tree Venture

Antios Therapeuticsantiostherapeutics.comin𝕏Series A · Apr 2021 · $96M

Antios Therapeutics develops antiviral therapies for hepatitis B virus (HBV) and other viral diseases, including its Active Site Polymerase Inhibitor Nucleotide (ASPIN) ATI-2173 and a capsid assembly modulator program.

BiotechHealthtechMendham, US

Gregory Mayes(Executive Officer, Director)Douglas Mayers(Executive Officer)inTamra Adams(Executive Officer)inAbel De La Rosa(Director)

BoardIyona Rajkomar(Director)inBenjamin Rovinski(Director)

Co-investorsAisling CapitalAltium CapitalAvego BioScience CapitalLifeSci Venture PartnersPontifax Venture CapitalAmzak Health+8 more

Applied Proteomicsappliedproteomics.comSeries B · Feb 2012 · $23M

Applied Proteomics develops a protein-based blood test for colorectal cancer risk assessment, offered to healthcare providers to evaluate patients' colorectal health during routine examinations.

BiotechHealthtech

Astute Medicalastutemedical.cominSeries B · May 2010 · $27M

bioMérieux develops in vitro diagnostic systems and molecular testing panels for pathogen detection in clinical, food safety, and pharmaceutical quality control settings.

BiotechHealthtechMedical DevicesSan Diego, US

Todd Myers(Executive Officer)inChristopher Hibberd(Executive Officer, Director)Kenneth Buechler(Director)Paul McPherson(Executive Officer, Director)

BoardJames Blair(Director)James Scopa(Director)

Co-investorsKaiser Permanente VenturesMoore Venture Partners

BiPar Sciencessanofi.usinSeries B · Feb 2007 · $35MAcquired

Biopharmaceutical developer of tumor-selective PARP inhibitor cancer therapies, acquired by Sanofi-aventis in 2009.

Co-investorsAisling CapitalAsset Management CompanyCanaan PartnersKleiner PerkinsSPRINGROCK VENTURESVantagePoint Capital Partners

ChromaCodechromacode.comin𝕏Series B · Apr 2017 · $12M

ChromaCode develops a High-Definition PCR (HDPCR) multiplexing platform that enables genomic solutions for oncology and precision medicine, offering faster results and cost-effective workflows through automated interpretation and cloud-based software.

AI & Machine LearningBiotechHealthtechMedical DevicesCarlsbad, US

Paul Flook(Executive Officer, Director)inGregory J. Gosch(Executive Officer, Director)Lynne Rollins(Executive Officer)Aditya Rajagopal(Director)inAxel Scherer(Director)

BoardJustin Klein(Director)in

Co-investorsAdjuvant CapitalGlobal BrainMoore Venture PartnersNew Enterprise Associates (NEA)Windham Capital PartnersDomain Partners+2 more

Coloresciencecolorescience.comSeries B · Sep 2014 · $15M

Colorescience is a professional skincare brand that develops mineral-based sun protection (SPF), skincare, and color correction products, originally created for post-procedure skin and marketed for all ages and skin types.

ConsumerDirect to ConsumerHealthtechWellness & FitnessCarlsbad, US

Stephen Loomis(Executive Officer)Mary Fisher(Executive Officer, Director)inTheodore Ebel(Executive Officer)Josie Juncal-Schwarz(Executive Officer)

BoardM Bolyard(Director)Brian Dovey(Director)in

Co-investors1315 CapitalAisling CapitalRevelation PartnersHealthCare Ventures, LLCLongwood FundMontreux Equity Partners+2 more

GenVaultgenvault.comin𝕏Feb 2011 · $15.6Macquired by Thermo Fisher Scientific

GenVault operates a GxP-compliant biorepository providing secure, temperature-controlled storage, sample management, and lab relocation services for biological, clinical, and biopharmaceutical materials.

BiotechHealthtechLogistics & Supply Chain

Co-investorsCross Creek AdvisorsQuestMark PartnersGreenspring AssociatesIn-Q-Tel

Locus Bioscienceslocus-bio.comin𝕏Feb 2024 · $152M

Locus Biosciences develops engineered bacteriophage therapies for treating bacterial infections and conditions in immunology, oncology, and CNS disorders.

AI & Machine LearningBiotechDeep TechHealthtechRaleigh, US

Paul Garofolo(CEO & Co-founder)NICK TAYLOR(Executive Officer)inNick Conley(Vice President of Technology (Co-founder of EpiBiome, acquired by Locus))in

BoardGEOFFREY GLASS(Director)inDAVID JOHNSTON(Director)BARY BAILEY(Director)

Co-investorsArtis VenturesAbstract VenturesHemisphere Ventures LLCLongitude CapitalStarlight VenturesTencent Holdings

Marinus Pharmaceuticalsmarinuspharma.comSeries A · Oct 2005 · $29M

BiotechRadnor, US

Scott Braunstein, MD(Executive Officer, Director)Edward F. Smith(Executive Officer)Joe Hulihan, MD(Executive Officer)

BoardNicole Vitullo(Director)Enrique J. Carrazana, MD(Director)Michael R. Dougherty(Director)

Co-investorsAvoro Capital AdvisorsBain Capital Life SciencesCanaan PartnersConnecticut InnovationsSofinnova VenturesFlare Capital Partners+1 more

Milestone Pharmaceuticalsmilestonepharma.comin𝕏

Milestone Pharmaceuticals is a life sciences company that develops therapies for patients with cardiovascular and other diseases.

BiotechDigital HealthHealthtechMedical DevicesMontreal, US

Ela Borenstein(Director)Francis Plat(Executive Officer)Yves Rosconi(Director)Scott Weiner(Director)Martin Maguire(Executive Officer)Philippe Douville(Executive Officer, Director)

Co-investorsPappas CapitalAmplitude Venture CapitalForbionRTW Investments L.P.

Omniomeomniome.comJan 2020 · $60MAcquired

San Diego DNA sequencing company behind the Sequencing by Binding short-read platform; acquired by Pacific Biosciences in 2021.

BiotechSan Diego, US

David S. Mullarkey(Executive Officer, Director)Arnold Oliphant(Executive Officer)inKen Song, M.D., Ph.D.(Executive Officer, Director)Kelly Perez(Executive Officer)John Murphy, Ph.D.(Executive Officer)Millard Y Chan(Chief Operating Officer, Secretary and Director)

Co-investorsARCH Venture PartnersATEL VenturesDCVC (Data Collective)Decheng CapitalLam CapitalPivotal Life Sciences+3 more

Orapharma Incorapharma.comin

OraPharma develops pharmaceutical products and tools for dental professionals to address oral health concerns, serving dental practices and patients.

HealthtechMedical DevicesBridgewater, US

Co-investorsA-Rod CorpCanaan PartnersFrazier Life SciencesHealthCapOak Investment Partners

RIGHTCARE SOLUTIONS, INC.rightcaresolutions.comSeries A · Oct 2012 · $2M

HealthtechHorsham, US

Eric Heil(Executive Officer, Director)

BoardDennis Podlesak(Director)Jesse Treu(Director)Richard Perlman(Director)Brian Murphy(Director)Peter Bach(Director)

Signifier Medical Technologiessignifiermedical.comSeries C · Sep 2020 · $10M

Signifier Medical Technologies is a medical device company developing non-invasive treatments for snoring and mild sleep apnea.

Digital HealthMedical DevicesWellness & Fitness

Akhil Tripathi(Co-founder)Phil Radford(Chairman)John Saville Bentley(Chief Executive Officer)Thomas McCarthy(Chief Financial Officer)

Thermo Fisher Scientificthermofisher.comin𝕏Feb 2014Acquired

Thermo Fisher provides life science products and laboratory equipment, including antibodies, consumables, biobanking resources, and Cryo-EM imaging systems for research labs and scientists.

BiotechEnterprise SoftwareHardwareHealthtechWaltham, US

Anthony Uzzo(Executive Officer, Director)inJoshua Geballe(Executive Officer, Director)James Gregory(Executive Officer, Director)Marc N. Casper(Executive Officer, Director)inAndrew J. Thomson(Executive Officer)Peter M. Wilver(Executive Officer)

Co-investorsARCH Venture PartnersBayMed Venture PartnersCross Creek AdvisorsEric F. ThiessenExcel Venture ManagementHeran Partners+6 more

Other

Tracked investments with no reachable website or further public details — typically companies that wound down, renamed, or were absorbed.

CoLucid PharmaceuticalsKona MedicalTragara PharmaceuticalsAxial BiotherapeuticsBenvenue MedicalCelator PharmaceuticalsCoDa TherapeuticsCortheraEsperionExalys TherapeuticsExelixisGene SciencesKalidex PharmaceuticalsMiramar LabsOcunexus TherapeuticsOtonomyRegado BiosciencesRevision OpticsSequent MedicalSomaxon PharmaceuticalsVentiRx PharmaceuticalsVerteroXagenicZyga Technology

Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.